IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Archive ouverte

Bazarbachi, Abdul Hamid | Avet-Loiseau, Hervé | Szalat, Raphael | Samur, Anil Aktas | Hunter, Zachary | Shammas, Masood | Corre, Jill | Fulciniti, Mariateresa | Anderson, Kenneth | Parmigiani, Giovanni | Treon, Steven | Mohty, Mohamad | Munshi, Nikhil | Samur, Mehmet Kemal

Edité par CCSD ; American Society of Hematology -

International audience. Abstract Immunoglobulin M (IgM) multiple myeloma (MM) is a rare disease subgroup. Its differentiation from other IgM-producing gammopathies such as Waldenström macroglobulinemia (WM) has not been well characterized but is essential for proper risk assessment and treatment. In this study, we investigated genomic and transcriptomic characteristics of IgM-MM samples using whole-genome and transcriptome sequencing to identify differentiating characteristics from non–IgM-MM and WM. Our results suggest that IgM-MM shares most of its defining structural variants and gene-expression profiling with MM, but has some key characteristics, including t(11;14) translocation, chromosome 6 and 13 deletion as well as distinct molecular and transcription-factor signatures. Furthermore, IgM-MM translocations were predominantly characterized by VHDHJH recombination-induced breakpoints, as opposed to the usual class-switching region breakpoints; coupled with its lack of class switching, these data favor a pre–germinal center origin. Finally, we found elevated expression of clinically relevant targets, including CD20 and Bruton tyrosine kinase, as well as high BCL2/BCL2L1 ratio in IgM-MM, providing potential for targeted therapeutics.

Consulter en ligne

Suggestions

Du même auteur

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Archive ouverte | Samur, Mehmet Kemal | CCSD

International audience. Abstract High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect ...

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Archive ouverte | Samur, Mehmet Kemal | CCSD

International audience. High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect on surviv...

Comprehensive Review of AL amyloidosis: some practical recommendations

Archive ouverte | Al Hamed, Rama | CCSD

International audience. Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and ...

Chargement des enrichissements...